Crescent Biopharma, Inc. CBIO
13.92 USD +0.27 (+1.98%)
At closeNov 10, 2026, 4:01 PM EST
13.92 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
13.27 Day range 14.05
8.72 52-week range 27.41
- YTD
- +17.37%
- 1 year
- +6.18%
News
globenewswire.com Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next…
globenewswire.com Crescent Biopharma to Present at November Investor Conferences WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next…
defenseworld.net Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC Wainwright Crescent Biopharma (NASDAQ: CBIO - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a report released on Monday, MarketBeat.com reports. They…
benzinga.com HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
benzinga.com Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027 Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027Phase 1/2 trial of CR-003 (SKB105), an…
globenewswire.com Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including…
globenewswire.com Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next…
benzinga.com HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.
benzinga.com Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
globenewswire.com Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
globenewswire.com Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Barbara Bispham sold 620 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 1,610 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,151.70 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Ellie Im sold 623 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells $10,167.20 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CFO Richard Scalzo sold 568 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at an…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,778.20 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Jan Pinkas sold 658 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an…
defenseworld.net Insider Selling: Crescent Biopharma (NASDAQ:CBIO) COO Sells $13,084.90 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 731 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of…
defenseworld.net Jonathan Mcneill Sells 3,839 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 3,839 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average…
defenseworld.net Joshua Brumm Sells 7,837 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 7,837 shares of the business's stock in a transaction dated Friday, September 18th. The stock was sold at an average…
defenseworld.net Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR) Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare…
seekingalpha.com Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
globenewswire.com Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the…
globenewswire.com Crescent Biopharma to Present at September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the…
benzinga.com Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
globenewswire.com Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next…
benzinga.com Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of…
benzinga.com Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms Undisclosed Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
benzinga.com This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.- benzinga.com Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027 Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today…
benzinga.com Crude Oil Down 3%; Chevron Posts Mixed Q1 Results Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
benzinga.com Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of…
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock- benzinga.com Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants This prospectus relates to the proposed resale or other disposition by the selling securityholders identified herein (the "Selling Securityholders") of up to (i) 13,664,251 (the "Private Placement…
benzinga.com HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.- benzinga.com Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35 Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
- benzinga.com Crescent Biopharma Announces Regulatory Clearances Of IND Applications For CR-001, PD-1 X VEGF Bispecific Antibody, And CR-003, ITGB6-Targeted ADC, For Treatment Of Advanced Solid Tumors CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with…
benzinga.com What's Happening With Crescent Biopharma Stock Today? Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.- benzinga.com Market-Moving News for December 4th PATH: 15% | UiPath shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance with its midpoint above estimates. SNOW: -9% | Snowflake
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Crescent Biopharma Secures $185M Private Placement; Investors To Purchase 13.8M Ordinary Shares At $13.41 Or Pre-Funded Warrants At $13.409 Private Placement FinancingCrescent also announced today that it entered into a securities purchase agreement for a private investment of securities to institutional and other accredited investors…
- benzinga.com Sichuan Kelun-Biotech And Crescent Biopharma Partner To Develop, Commercialize Oncology Therapeutics; Cos To Advance CR-001, PD-1 x VEGF Bispecific Antibody, And SKB105 In Global Markets And China Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and ChinaCollaboration designed to accelerate…